GMED Q3 2026 deep dive: product launch delays and Nevro drag outlook, margin improvement offsets
Why Globus Medical (GMED) shares are plunging today
Globus Medical to Participate in Jefferies Global Healthcare Conference
Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $90
Globus Medical Inc (GMED) Q3 2026 Earnings Call Highlights: Revenue Miss, Nevro Weakness and ...
Globus Medical Q3 Earnings Call Highlights
BMO Capital Downgrades Globus Medical to Market Perform from Outperform
Canaccord Genuity Maintains Buy on Globus Medical, Lowers Price Target to $105
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset
Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $100
Needham Maintains Buy on Globus Medical, Lowers Price Target to $100
Globus Medical (GMED) Q3 2026 Earnings Call Transcript
BMO Capital Downgrades Globus Medical to Market Perform, Lowers Price Target to $78
Compared to Estimates, Globus Medical (GMED) Q3 Earnings: A Look at Key Metrics
Globus Medical (NYSE:GMED) reports sales below analyst estimates in Q3 2026 earnings
Globus Medical: Q3 Earnings Snapshot
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program
Globus Medical, Inc. (GMED) Q3 2026 Earnings Call Transcript
Globus Medical Q3 2026 Earnings Call Transcript
Globus Medical Q3 Adj. EPS $1.23 Beats $1.20 Estimate, Sales $763.719M Miss $792.415M Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.